Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2715907 | 0.77 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL4283523 | 0.73 | DRD2 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL3980581 | 0.73 | POLB (0.38) | DRD2DRD4DRD3HRH3 | |
| Hydrochloric Acid SCHEMBL31352065 | 0.71 | POLB (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL23938200 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL13564548 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL6930142 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL4126928 | 0.68 | TRIM24 (0.36) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL21580175 | 0.68 | DRD2 (0.33) | DRD2DRD4DRD3HRH3 | |
| SCHEMBL13603599 | 0.68 | DRD2 (0.46) | DRD2DRD4DRD3HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | claimed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | claimed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | claimed |
| EP-4185564-A1 | TRICYCLIC HETEROCYCLES | Merck Patent GmbH (DE) | 2023-05-31 | — | — | EP | claimed |
| WO-2023078813-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2023-05-11 | — | — | WO | claimed |
| EP-4146652-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | Merck Patent GmbH (DE) | 2023-03-15 | — | — | EP | claimed |
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2022-05-05 | — | — | US | claimed |
| WO-2021224291-A1 | TRICYCLIC HETEROCYCLES USEFUL AS TEAD BINDERS | MERCK PATENT GMBH (DE) | 2021-11-11 | — | — | WO | claimed |
| EP-3818063-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-05-12 | — | — | EP | claimed |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | claimed |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4334319-A1 | 2,8-DIHYDROPYRAZOLO[3,4-B]INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Merck Patent GmbH (DE) | 2024-03-13 | — | — | EP | disclosed |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230192628-A1 | MICROBIOCIDAL DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2023-06-22 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| EP-3818063-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | Incyte Corporation (US) | 2021-05-12 | — | — | EP | disclosed |
| WO-2020239853-A1 | MICROBIOCIDAL DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2020-12-03 | — | — | WO | disclosed |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2020-01-30 | — | — | US | disclosed |
| WO-2009152027-A1 | 5,7-DIHYDRO-6H-PYRROLO[2,3-D]PYRIMIDIN-6-ONE DERIVATIVES FOR MARK INHIBITION | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135570-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | DRD2 1202/4885DRD4 3359/4885DRD3 2304/4885 |
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | DRD2 4711/4885DRD4 4737/4885DRD3 4576/4885 |
| US-20200031835-A1 | FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | DRD2 1202/4885DRD4 3359/4885DRD3 2304/4885 |
| US-11161850-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | DRD2 1202/4885DRD4 3359/4885DRD3 2304/4885 |
| US-20230192628-A1 | MICROBIOCIDAL DERIVATIVES | MPO, PRF1, MSR1 | DRD2 935/4885DRD4 514/4885DRD3 511/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | DRD2 4638/4885DRD4 4697/4885DRD3 4501/4885 |
| US-11999740-B2 | Fused pyrazine derivatives as A2A / A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | DRD2 1202/4885DRD4 3359/4885DRD3 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.